about
Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodiesVariation in healthcare services for specialist genetic testing and implications for planning genetic services: the example of inherited retinal dystrophy in the English NHS.Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.Risk factors for onset of chronic oro-facial pain--results of the North Cheshire oro-facial pain prospective population studyEarly treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis.Association of a rheumatoid arthritis susceptibility variant at the CCL21 locus with premature mortality in inflammatory polyarthritis patientsExcess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis.The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register.Mechanism-based urinary biomarkers to identify the potential for aminoglycoside-induced nephrotoxicity in premature neonates: a proof-of-concept study.Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis.Understanding the impacts of care farms on health and well-being of disadvantaged populations: a protocol of the Evaluating Community Orders (ECO) pilot study.Parity, time since last live birth and long-term functional outcome: a study of women participating in the Norfolk Arthritis RegisterEarly functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register.Seropositivity is associated with insulin resistance in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR): an observational study.Prevalence, Nature, Severity and Risk Factors for Prescribing Errors in Hospital Inpatients: Prospective Study in 20 UK Hospitals.Association of functional outcome with both personal- and area-level socioeconomic inequalities in patients with inflammatory polyarthritisGeographical inequalities in uptake of NHS funded eye examinations: Poisson modelling of small-area data for Essex, UK.The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis.Are differences in travel time or distance to healthcare for adults in global north countries associated with an impact on health outcomes? A systematic review.Association between Clostridium difficile infection and antimicrobial usage in a large group of English hospitals.Variations in dementia diagnosis in England and association with general practice characteristics.Empirically derived cut-points for sedentary behaviour: are we sitting differently?Injecting drug use in prison: prevalence and implications for needle exchange policy.The MRSA-import in ICUs is an important predictor for the occurrence of nosocomial MRSA cases.A genetic marker at the OLIG3/TNFAIP3 locus associates with methotrexate continuation in early inflammatory polyarthritis: results from the Norfolk Arthritis Register.Geographical inequalities in uptake of NHS-funded eye examinations: small area analysis of Leeds, UK.Why do patients with inflammatory arthritis often score states "worse than death" on the EQ-5D? An Investigation of the EQ-5D classification system.Assessing the impact of care farms on quality of life and offending: a pilot study among probation service users in England.The relationship between oral contraceptive use and functional outcome in women with recent-onset inflammatory polyarthritis: Results from the Norfolk Arthritis RegisterReply to letter by Lippi et al commenting on the relationship between serum vitamin D levels and levels of inflammation markersAssociation between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritisVitreoretinal interface abnormalities in middle-aged adults with visual impairment in the UK Biobank study: prevalence, impact on visual acuity and associationsMonocular and binocular visual impairment in the UK Biobank study: prevalence, associations and diagnosesSpecialist palliative care support is associated with improved pain relief at home during the last 3 months of life in patients with advanced disease: analysis of 5-year data from the national survey of bereaved people (VOICES)Depression and anxiety in patients with multidrug-resistant tuberculosis in Nepal: an observational studyThe Impact of Therapists' Responses to Resistance to Change: A Sequential Analysis of Therapist Client Interactions in Motivational InterviewingFactors Affecting Patients' Use of Electronic Personal Health Records in England: Cross-Sectional Study
P50
Q24627677-A302F706-EB32-423F-A1FA-98870F01DAEAQ30626900-2EE0A377-D560-4BE5-9BD1-D6F9030AF8DCQ33646340-01BFCC49-0459-4197-BF26-0730CC509A13Q33882295-09EC6434-AA86-4071-85CA-22F67A5FF16BQ34081871-C7825558-ACF8-460E-A085-0A46794E4BBDQ34113334-EBECD211-1715-425B-867E-63A7CB3DABB2Q34125171-E72ECF25-C0C2-462A-8F32-BF3EC19DFE79Q34395284-BEB7A19B-ACFA-4DA8-9408-679F3DD4D69FQ34399423-FEF624C6-60E2-4874-8DA6-5D2DACCF12DFQ34401259-EA606F19-07A9-4BD7-953E-6F82B41A8635Q34439027-4D22B357-4218-4B88-8EAA-28EF9DAF46CFQ35537108-5C857A3C-FF12-47AD-9712-1CC3ED84315CQ35760080-C5F5EEB2-DD91-48C6-AC8B-ABD5379328C5Q35840769-F3A6AFCB-6EB3-4D19-9402-91BB8F713E93Q36034371-85A84F79-AE8E-433F-AF18-B8405EC0FDD7Q36388001-B8F77926-C4F5-4E44-9120-CC9438E364CFQ36410627-BD8EA58E-AA72-4A8B-83F1-7EDAC785C79AQ37173846-92373537-C882-44E1-B9E4-1CF74477A298Q37527143-C9E5165E-ED64-4EA3-8167-06B66585A7CDQ37731876-A08E1139-A576-4F9C-9077-553D31AD2CAEQ38928039-14B972C4-F22F-477A-AB38-0793C01164B8Q39367044-1B259520-DCBE-4697-AE95-5EC2B224C7D8Q41267017-74B7136D-7795-436A-9E05-A8DCCF75592FQ43499904-8E214A8E-301F-4EC9-BBC8-6999F222B0FFQ45252920-81C08113-888B-464B-B0C5-78591290E789Q50110835-FA9E507C-89A3-4A24-A8EF-B88B11D48C56Q51827038-0E38D83C-B6AF-4F07-A789-6291B102BDC9Q52802727-BB83BF75-5BDD-4D0E-BB7B-E7149675B0B6Q56332492-C2920671-6DEE-42E4-98F8-CE593BAFD59BQ56332505-23D09807-49C2-492F-89EF-25196BE86D00Q56332508-87CC748D-58D2-4020-8AA4-E438285DF50CQ57652628-953FF2D2-90FC-440D-8B39-6DE20945C2D4Q59885498-76508B01-A41D-403A-B55C-39F39259F7B3Q64059780-21BCD568-6859-433A-9498-E5179DFD6980Q64067744-22F7701B-37BC-4D50-93ED-CD4EC8FBB2A2Q91848103-C964AC78-E664-4268-8F82-1A519797E908Q92332601-54AEBF32-5D9B-4651-B5A6-43707E83A47D
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
researcher
@en-gb
հետազոտող
@hy
name
Tracey Farragher
@ast
Tracey Farragher
@cy
Tracey Farragher
@en
Tracey Farragher
@en-gb
Tracey Farragher
@es
Tracey Farragher
@nl
Tracey Farragher
@sl
type
label
Tracey Farragher
@ast
Tracey Farragher
@cy
Tracey Farragher
@en
Tracey Farragher
@en-gb
Tracey Farragher
@es
Tracey Farragher
@nl
Tracey Farragher
@sl
prefLabel
Tracey Farragher
@ast
Tracey Farragher
@cy
Tracey Farragher
@en
Tracey Farragher
@en-gb
Tracey Farragher
@es
Tracey Farragher
@nl
Tracey Farragher
@sl
P106
P1153
15062873200
P21
P31
P496
0000-0002-1968-6378